Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
| Autor: | Sallman, David A., DeZern, Amy E., Gayle, Arlene A., Kahn, Stuart J. *, Padron, Eric, Lancet, Jeffrey E., Kuykendall, Andrew, Sweet, Kendra, Chan, Onyee, Maeda, Dean Y. *, Schuler, Aaron D. *, Zebala, John A. *, Komrokji, Rami S. |
|---|---|
| Zdroj: | In Blood 15 November 2022 140 Supplement 1:2070-2072 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|